SWOG clinical trial number
CTSU/C10701

A Phase II Study of Dasatinib(Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG AND SWOG

Closed
Phase
Abbreviated Title
PII Dasatinib/Transplant for New Ph+ ALL >/= 50
Activated
06/01/2012
Closed
11/14/2014
Participants
NCORP, Members, Medical Oncologists, CTSU, Affiliates

Research committees

Leukemia

Treatment

Dasatinib

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL

M Wieduwilt;J Yin;M Wetzler;G Uy;B Powell;J Kolitz;M Liedtke;W Stock;J Beumer;R Mattison;E Storrick;S Christner;L Lewis;S Devine;R Stone;R Larson Blood Advances, Nov 23;5(22):4691-4700

PMid: PMID34492682 | PMC number: PMC8759134

2018

A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

M Wieduwilt;J Yin;M Wetzler;G Uy;B Powell;J Kolitz;M Liedtke;W Stock;JH Beumer;R Mattsion;A Halvorson;S Devine;RM Stone;RA Larson Blood 132:309; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral

2016

A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

MJ Wieduwilt;J Yin;M Wetzler;G Uy;BL Powell;J Kolitz;M Liedtke;W Stock;J Beumer;R Mattison;A Halvorson;S Devine;R Stone;R Larson Blood 2016 128:2782; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster

Other Clinical Trials

SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase